Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Non-cash Items (2016 - 2024)

Historic Non-cash Items for Ernexa Therapeutics (ERNA) over the last 11 years, with Q4 2024 value amounting to $2.3 million.

  • Ernexa Therapeutics' Non-cash Items rose 38333323333.33% to $2.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.3 million, marking a year-over-year increase of 38333323333.33%. This contributed to the annual value of $2.3 million for FY2024, which is 38333323333.33% up from last year.
  • Ernexa Therapeutics' Non-cash Items amounted to $2.3 million in Q4 2024, which was up 38333323333.33% from $0.6 recorded in Q4 2023.
  • In the past 5 years, Ernexa Therapeutics' Non-cash Items ranged from a high of $18.5 million in Q1 2022 and a low of -$853881.0 during Q1 2020
  • For the 5-year period, Ernexa Therapeutics' Non-cash Items averaged around $6.8 million, with its median value being $2.3 million (2024).
  • Per our database at Business Quant, Ernexa Therapeutics' Non-cash Items skyrocketed by 2962.07% in 2022 and then surged by 38333323333.33% in 2024.
  • Over the past 5 years, Ernexa Therapeutics' Non-cash Items (Quarter) stood at -$853881.0 in 2020, then skyrocketed by 1771.47% to $14.3 million in 2021, then increased by 29.62% to $18.5 million in 2022, then crashed by 100.0% to $0.6 in 2023, then skyrocketed by 383333233.33% to $2.3 million in 2024.
  • Its Non-cash Items was $2.3 million in Q4 2024, compared to $0.6 in Q4 2023 and $18.5 million in Q1 2022.